Genmab — September 2016
-
"f this antibody is mobilizing the immune system in a way that it reduces the B- and T-regulatory cells [that inhibit T-cell function] and MDSCs, whether it can be another immune checkpoint inhibitor and whether we can combine it with other antibodies or cytotoxic therapies in various other solid tumors is [an open question]. I see that in the future we will see these types of studies with daratumumab".
-
Vi begynder at ane, hvorfra Jan van de Winkels selvtillid stammer fra.
-
Jeg nævner: Keytruda, Opdivo, Tecendriq og Yervoy http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/immunotherapy/cancer-immunotherapy-immune-checkpoint-inhibitors
-
Og de er stor Bulder.
-
OHW...Der er mange indikationer omkring den eventuelle bredspektrede virkning som man får undervejs i forskellige studier.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind